fludrocortisone acetate - Profile

What are the generic sources for fludrocortisone acetate and what is the scope of patent protection?

Fludrocortisone acetate is the generic ingredient in two branded drugs marketed by Casper Pharma Llc, Barr, Chartwell Rx, Hibrow Hlthcare, Hikma Pharms, Impax Labs, Novitium Pharma, and Zydus Lifesciences, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

Summary for fludrocortisone acetate

US Patents:	0
Tradenames:	2
Applicants:	8
NDAs:	8

US Patents and Regulatory Information for fludrocortisone acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Casper Pharma Llc	FLORINEF	fludrocortisone acetate	TABLET;ORAL	010060-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Barr	FLUDROCORTISONE ACETATE	fludrocortisone acetate	TABLET;ORAL	040425-001	Jan 21, 2003		DISCN	No	No
Chartwell Rx	FLUDROCORTISONE ACETATE	fludrocortisone acetate	TABLET;ORAL	216013-001	Oct 27, 2022		DISCN	No	No

Last updated: July 24, 2026

Fludrocortisone Acetate Investment Scenario and Patent/Regulatory Fundamentals Analysis (2026)

Fludrocortisone acetate is a mature, off-patent steroid used in primary adrenal insufficiency (Addison’s disease) and certain salt-wasting states. The investment thesis is driven by (1) long-running generic market depth in the US, (2) steady demand tied to chronic endocrine care, and (3) incremental, form-factor and labeling-derived differentiation rather than near-term patent exclusivity. Any value expansion will come from narrow lifecycle protection (if any), product-specific manufacturing/quality barriers, payer positioning, and regional supply stability, not from brand-level exclusivity.

What is fludrocortisone acetate used for, and how does demand behave for chronic adrenal insufficiency therapies?

Fludrocortisone acetate is used primarily for:

• Primary adrenal insufficiency (to replace mineralocorticoid function)
• Salt-wasting congenital adrenal hyperplasia (in practice, often as part of broader management)
• Other salt-wasting disorders, based on clinician judgment and local labeling

Demand profile

• Chronic, life-long or long-duration treatment for many patients.
• High adherence dependence on dose stability and tolerability.
• Demand tends to be resilient versus economic cycles because endocrine replacement therapy is medically necessary.

Commercial implication

• Growth is generally low-single-digit and substitution-driven. Value is constrained by generic competition unless a product has a demonstrable differentiation edge (packaging, dosing convenience, stability, supply reliability, or negotiated payer access).

What is the FDA regulatory status of fludrocortisone acetate, and how does it shape generic and AB-rated competition?

Fludrocortisone acetate is an established small-molecule product approved under US FDA pathways that historically have resulted in extensive generic entry.

Core investment implication of regulatory status

• Expect rapid, broad AB-generic substitutability in most markets that maintain coverage of adrenal insufficiency products.
• Pricing power is typically limited to:
  • Contract/wholesaler rebates
  • Short-term supply disruptions
  • Specific dosage-form availability constraints (when a manufacturer exits, quality issues emerge, or procurement tightens)

Practical consequence

• New entrants typically target cost leadership or supply reliability rather than clinical differentiation.

What patents protect fludrocortisone acetate in the US, and how many expire when?

No credible investment-grade patent estate can be assessed from the information provided here. A complete and accurate protection timeline requires specific Orange Book records (listed drug numbers, application holders, and patent identifiers) and/or published patent families tied to the specific approved formulation(s) and methods of use. Without those records, any statement about patent protection would be speculative and not suitable for litigation or licensing decisioning.

What is the Orange Book status of fludrocortisone acetate, and which patents are listed for US approval?

A complete Orange Book status requires the drug’s exact FDA “Listed Drug” entry and the associated patent list. The prompt does not include those identifiers. Without them, it is not possible to produce a correct enumeration of patents (formulation, method-of-use, polymorph, manufacturing) or to map each patent to expiration and litigation posture.

When does fludrocortisone acetate lose exclusivity, and what are the practical generic entry windows?

Because the patent and exclusivity facts (Orange Book patent expiry dates, pediatric exclusivity, patent term adjustments, and any granted exclusivity such as data exclusivity for specific dosage forms) are not provided, the exclusivity loss timing cannot be stated accurately.

How many Paragraph IV challenges exist for fludrocortisone acetate, and which companies have filed?

A reliable count of Paragraph IV filings and challengers requires access to FDA Paragraph IV litigation dockets and the drug’s specific ANDA submissions. That docket data is not included here, so a factual assessment cannot be produced.

What patent litigation affects fludrocortisone acetate, and who are the parties?

Patent litigation requires case captions, jurisdictions, and docket numbers to support fact patterns. None are provided, so no litigation status can be reported as “hard data.”

What formulations are protected by fludrocortisone acetate patents, including strengths, dosage forms, and manufacturing methods?

Formulation and manufacturing protections are only determinable from listed patents tied to specific dosage strengths and dosage forms in the FDA Orange Book, plus any published patents covering process steps. That dataset is not present in the prompt, so no accurate claim-by-claim or family-by-family protection map can be generated.

How does fludrocortisone acetate compare with alternative mineralocorticoid replacement products in investment fundamentals?

For investors, competitive substitution and payer coverage are the key comparators, not clinical superiority. In practice, the competitive set typically includes:

• Other mineralocorticoid replacement options used for similar indications (where marketed and covered)
• Different steroid replacement regimens that might reduce reliance on a specific mineralocorticoid formulation

Investment implication

• If meaningful therapeutic alternatives exist with better access or fewer supply constraints, fludrocortisone acetate faces volume elasticity even when the indication is chronic.
• If alternatives are limited and coverage is sticky, generic entrants compete mostly on price and supply rather than on clinical outcomes.

What generic entry risks exist for fludrocortisone acetate, and what manufacturing/IP barriers matter?

Key generic-entry risks that affect margins:

• Supply chain stability: raw material sourcing and sterile vs non-sterile manufacturing quality controls (fludrocortisone acetate is oral, so sterile risk is lower than injectables but solid oral manufacturing and containment still matter)
• Quality consistency: assay, impurities, stability, and dissolution specifications
• Regulatory inspections: warning letters, consent decrees, and batch release constraints can temporarily protect incumbent share
• Form-factor constraints: if only a few strengths are commercially robust, investors should evaluate which SKUs are most exposed to discontinuations

IP barriers are generally weaker for mature oral steroids unless there is a specific, still-live formulation or process patent tied to a particular listed product.

What is the competitive landscape for fludrocortisone acetate in the US, and where can incumbents defend share?

With extensive generic availability expected for mature products, defense typically comes from:

• Contract coverage with large payers and pharmacy benefit managers
• National accounts distribution agreements
• Inventory depth and manufacturing redundancy to reduce out-of-stock events
• Field inventory tactics around seasonal or shortage-driven procurement cycles

Investment implication

• The core risk is price compression across competitors. The core upside is supply reliability and negotiated access that temporarily stabilizes net price.

Revenue exposure: what drives fludrocortisone acetate unit growth versus margin decline?

For mature generics, revenue trends usually separate into:

• Units: driven by patient prevalence, adherence, and prescriber patterns
• Net price: driven by competitive pricing, wholesaler spreads, and formulary status

Investment implication

• Expect margin pressure unless a company controls supply capacity or has a structural distribution advantage.
• Business case depends on cost-of-goods control, procurement scale, and avoiding regulatory disruptions.

Key diligence checklist for an investment in a fludrocortisone acetate manufacturer or product platform

Without patent and Orange Book facts in the prompt, diligence should focus on operational and regulatory risk items that drive realized earnings for mature generics:

1. US supply footprint: number of lots per year, batch failure history, and historical out-of-stock incidents
2. Regulatory posture: inspection cadence, observations history, and CAPA timelines
3. Manufacturing economics: fixed cost absorption and API input cost volatility
4. Product portfolio concentration: exposure to only one SKU versus multi-SKU batching flexibility
5. Customer concentration: wholesale and payer contract dependency
6. Quality system maturity: deviation rates, OOS/OOT events, and trend quality

Key Takeaways

• Fludrocortisone acetate is a chronic endocrine replacement therapy with demand resilience but structurally limited pricing power due to generic substitutability.
• Investment upside is likely supply- and access-driven rather than exclusivity-driven.
• A rigorous patent-and-exclusivity view cannot be produced from the information provided; any decision that depends on exact Orange Book listings, expiration dates, or Paragraph IV posture requires those records.
• Operational execution and regulatory risk management are the dominant determinants of margins for mature oral generics like fludrocortisone acetate.

FAQs

Is fludrocortisone acetate a brand or generic-only market in the US?

It is treated commercially as a mature product with extensive generic availability in the US market.

What shortages most commonly threaten availability for fludrocortisone acetate?

Availability risk typically stems from manufacturing capacity limits, quality events that delay release, or raw-material procurement constraints.

Does fludrocortisone acetate have meaningful clinical differentiation versus other endocrine therapies?

Investment fundamentals generally depend more on payer access and product availability than on unique clinical differentiation, given the replacement nature of therapy.

What regulatory events would most impact earnings for a fludrocortisone acetate manufacturer?

US inspections leading to import bans, warning letters, or quality-system remediation delays are the most direct earnings disruptors via delayed batch release.

What evidence supports sustained pricing in mature steroid generics?

Consistent supply, broad wholesaler distribution, and contract formulary access that limits switching behavior are the key supports.

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. FDA. ANDA Patent Information for Drugs Submitted Under Section 505(j) of the FD&C Act. U.S. Food and Drug Administration. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda